Retatrutide, also known as “Triple G,” is the new weight loss injection making waves in the diet industry. Unlike Semaglutide, which targets GLP-1, and Tirzepatide, which targets GLP-1 and GIP, Retatrutide uniquely targets GLP-1, GIP, and glucagon. This makes it the only injectable to address all three hunger-regulating hormones, giving it its “Triple G” name.
Retatrutide not only promotes more substantial weight loss—up to 28% faster than Semaglutide or Tirzepatide—but also repairs fatty liver disease. A Phase 2 clinical trial published in The New England Journal of Medicine reported a 17.5% mean weight loss reduction at 24 weeks in overweight and obese adults. While still an investigational treatment, Retatrutide shows promise by stimulating insulin secretion through GIP and GLP-1, and boosting glucose production in the liver via glucagon.
Currently in its final trial stages, Retatrutide is available off-label but is expected to see high demand upon FDA approval. Call us today to discuss this once-weekly injectable and be among the first to try this groundbreaking weight loss solution!